Effectiveness of photodynamic therapy in Bowen's disease: a retrospective observational study in 423 lesions

Zaar, Oscar; Fougelberg, Julia; Hermansson, Anna-Karin; Gillstedt, Martin; Wennberg-Larkö, A.-M.; Paoli, John

doi:10.1111/jdv.14164

Cited by 35 publications

(31 citation statements)

References 19 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Most studies of this question are based on small case series, and report failure rates ranging from 50% to 100%, while larger-scale studies have observed recurrence rates of 64.5-77.5%. 11,12 However, these studies are heterogeneous, with a variety of illumination sources, wavelengths, photosensitisers and dosing schedules (a single session is usually less effective than two or more sessions). Hence, comparisons may be difficult to interpret.…”

Section: Discussionmentioning

confidence: 99%

Long‐term efficacy of photodynamic therapy with methyl aminolevulinate in treating Bowen's disease in clinical practice: A retrospective cohort study (2006‐2017)

Aguilar-Bernier

Rodríguez-Barón

Rivas-Ruiz

et al. 2019

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

Background: Photodynamic treatment with methyl aminolevulinate (MAL-PDT) is considered an effective and highly recommended treatment for Bowen's disease.However, its long-term efficacy remains to be established, as significant differences have been reported in this respect. Objective:The aim of the present study was to describe the results of a retrospective analysis of patients with Bowen's disease treated with MAL-PDT during the period 2006-17 at the Costa del Sol Hospital (Marbella, Spain). Material and Methods: This study is based on a retrospective descriptive analysis of the clinical records of patients treated with MAL-PDT from June 2006 to September 2017. The analysis was based on calculating the mean and standard deviation values for the quantitative variables, and frequency distributions for the qualitative ones.The survival curves were plotted by the Kaplan-Meier method, and the log-rank test was used to assess differences in survival between groups. A cox regression analysis was performed to clarify the significant prognostic factors. Results:A total of 537 tumours with histologically confirmed Bowen's disease were treated with MAL-PDT. Recurrence-free survival at one year was 88%, and at 5 years, 71%. Tumour size >300 mm 2 (≥21 mm in diameter P = 0.019), its location in the upper extremities (P = 0.029) and patient's age <70 years (P = 0.028) were all associated with an increased risk of recurrence. Limitations:Given the retrospective design of our study, the possible existence of information bias cannot be ruled out. Conclusions:Although it is an appropriate treatment option for patients with Bowen's disease, MAL-PDT presents a risk of recurrence of almost 30% at 5 years. Larger lesions (>300 mm 2 ; ≥21 mm in diameter) are more likely to recur than smaller ones. Therefore, appropriate selection is needed of the tumour to be treated, and prolonged follow-up should be provided.

show abstract

Section: Discussionmentioning

confidence: 99%

Long‐term efficacy of photodynamic therapy with methyl aminolevulinate in treating Bowen's disease in clinical practice: A retrospective cohort study (2006‐2017)

Aguilar-Bernier

Rodríguez-Barón

Rivas-Ruiz

et al. 2019

Photoderm Photoimm Photomed

View full text Add to dashboard Cite

show abstract

“…The rates of clearance in this tertiary public dermatology outpatient clinic are comparable to, but overall lower than published rates, 4 with the exception of nodular BCC (n = 2). Direct comparisons are difficult due to differences in published treatment protocols.…”

mentioning

confidence: 46%

“…The Brown School of Public Health Meta-Analysis software was used for analysis. 3,4 Of the 170 studies screened following the literature search, the inclusion criteria were met in 15 (Supplementary Fig. 1).…”

mentioning

confidence: 99%

Photodynamic therapy: A real‐world analysis of outcomes of photodynamic therapy in an Australian tertiary dermatology clinic

et al. 2019

View full text Add to dashboard Cite

“…1 Breslow thickness is an important determinant of prognosis. [2][3][4] In Western Australia, between 2000 and 2011, the median Breslow thickness of melanomas increased. 5,6 Previous studies have shown a positive association between age and male gender, and Breslow thickness.…”

Section: Factors Affecting Breslow Thickness: Results From a Survey Omentioning

confidence: 99%

Systematic review and meta‐analysis of surgical site infection following Mohs surgery without prophylactic antibiotics

Smith¹,

Borchard²,

Cherian³

et al. 2019

Aust J Dermatology

View full text Add to dashboard Cite

Effectiveness of photodynamic therapy in Bowen's disease: a retrospective observational study in 423 lesions

Abstract: This study shows that PDT is a relatively effective treatment modality for BD.

Cited by 35 publications

References 19 publications

Long‐term efficacy of photodynamic therapy with methyl aminolevulinate in treating Bowen's disease in clinical practice: A retrospective cohort study (2006‐2017)

Long‐term efficacy of photodynamic therapy with methyl aminolevulinate in treating Bowen's disease in clinical practice: A retrospective cohort study (2006‐2017)

Photodynamic therapy: A real‐world analysis of outcomes of photodynamic therapy in an Australian tertiary dermatology clinic

Systematic review and meta‐analysis of surgical site infection following Mohs surgery without prophylactic antibiotics

Contact Info

Product

Resources

About